Goldman Sachs resets Pfizer stock forecast
Pfizer has spent the past few years trying to convince investors that its post-pandemic business can stand on its own, and Goldman Sachs appears to be asking for more proof before getting more bullish on the stock. Goldman Sachs analyst Asad Haider maintained a hold rating on Pfizer and lowered his price target to $26, […]
Goldman Sachs resets Pfizer stock forecast Read More »
